Immunodiagnostic Value of Combined Detection of Autoantibodies to Tumor-associated Antigens as Biomarkers in Pancreatic Cancer

Scandinavian Journal of Immunology

Volumn 75, Issue 3, 2012, Pages 342-349

  Li, J ^a   Wang, L J ^a   Ying, X ^a   Han, S X ^a   Bai, E ^a   Zhang, Y ^a   Zhu, Q ^a  

^a THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CA 19-9 ANTIGEN; PROTEIN P16; PROTEIN P53; PROTEIN P62; SURVIVIN; TUMOR ANTIGEN;

ADULT; AGED; ANTIBODY DETECTION; ANTIGEN ANTIBODY REACTION; ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; OUTCOME ASSESSMENT; PANCREAS CANCER; PREDICTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; AUTOANTIBODIES; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84863170916     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2011.02657.x     Document Type: Article

References (31)

1. Tan EM. Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis. J Clin Invest 2001;108:1411-5.
2. Tan EM, Zhang J. Autoantibodies to tumor-associated antigens: reporters from the immune system. Immunol Rev 2008;222:328-40.
3. Wang H. Commonly used tumor markers. Detection and Clinical Application of Tumor Markers. Hefei: Publishing company of scientific technology, 2007:148-216. ISBN: 9787533738570.
4. Livingston PO, Ragupathi G, Musselli C. Auto- immune and antitumor consequences of antibodies against antigens shared by normal and malignant tissues. Clin Immunol 2000;20:85-93.
5. Soussi T. p53 Antibodies in the sera of patients with various types of cancer. Cancer Res 2010;60:1777-88.
6. Zhang JY, Chan EKL, Peng XX et al. A novel cytoplasmic protein with RNA- binding motifs is an autoantigen in human hepatocellular carcinoma. J Exp Med 1999;189:1101-10.
7. Tong YQ, Zhang ZJ, Liu B et al. Autoantibodies as potential biomarkers for nasopharyngeal carcinoma. Proteomics 2008;8:3185-93.
8. Zhang JY, Zhu W, Imai H et al. De-novo humoral immune response to cancer-associated autoantigens during transition from chronic liver disease to hepatocellular carcinoma. Clin Immunol 2001;125:3-9.
9. Parkin DM, Bray F, Ferlay J et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
10. Han SS, Kim SW, Jang JY et al. A comparison of the long-term functional outcomes of standard pancreatoduodenectomy and pylorus-preserving pancreatoduodenectomy. Hepatogastroenterology 2007;54:1831-5.
11. Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 2007;33:266-70.
12. Kim BJ, Lee KT, Moon TG et al. How do we interpret an elevated carbohydrate antigen 19-9 level in asymptomatic subjects? Dig Liver 2009;41:364-9.
13. Zhang JY, Casiano CA, Peng XX et al. Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomarkers Prev 2003;12:136-43.
14. Muller-Pillasch F, Lacher U, Wallrapp C et al. Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein. Oncogene 1997;14:2729-33.
15. Nielsen J, Christiansen J, Lykke-Andersen J, Johnsen AH, Wewer UM, Nielsen FC. A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol Cell Biol 1999;19:1262-70.
16. Rubin RL. Enzyme-linked immunosorbent assays for antibodies to native DNA, histones, and (H2A-H2B)-DNA. In: Rose NR, Conway de Macario E, Folds JD, Lane HC, Nakamura RM, eds. Manual of Clinical Laboratory Immunology. Washington, DC: American Society for Microbiology, 1997:935-41. ISBN: 9781555811181.
17. Chen WQ. Assessing the validity and reliability of screening test. In: Li LM, ed. Epidemiology. Beijing: Publishing company of the people' health, 2004:289-92. ISBN: 7117061995.
18. Koksun L, Roxanne M, Fu DS et al. Humoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies. Oncol Rep 2006;16:1105-10.
19. Lu M, Nakamura RM, Dent ED et al. Aberrant expression of fetal RNA-binding protein p62 in liver cancer and liver cirrhosis. Am J Pathol 2001;159:945-53.
20. Zhang JY, Chan EKL. Autoantibodies to IGF-II RNA binding protein p62 and overexpression of p62 in human hepatocellular carcinoma. Autoimmun Rev 2002;1:146-53.
21. Zhang JY, Chan EK, Peng XX et al. Autoimmune responses to mRNA binding proteins p62 and Koc in diverse malignancies. Clin Immunol 2001;100:149-56.
22. Rohyaem J, Diestelkoetter P, Weigle B et al. Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients. Cancer Res 2000;60:1815-7.
23. TSuburaya A, Noguehi Y, Yoshikawa T et al. An anti-apoptosis gene, survivin and telomerase ex- pression in gastric cancer. Hepato gastroenterology 2002;49:1150-2.
24. Wang X, Yu J, Sreekumar A et al. Autoantibody signatures in prostate cancer. N Engl J Med 2006;353:1224-35.
25. Lubin R, Zalcman G, Bouchet L et al. Serum p53 antibodies as early markers of lung cancer. Nat Med 1995;1:701-2.
26. Zalcman G, Schlichtholz B, Tredaniel J et al. Monitoring of p53 autoantibodies in lung cancer during therapy. Relationship to response to treatment. Clin Cancer Res 1998;4:1359-66.
27. Mirna L, Josip L, Stanislav L et al. Humoral immune response to p53 correlates with clinical course in colorectal cancer patients during adjuvant chemo- therapy. Int J Colorecal Dis 2004;19:114-20.
28. Dong M, Nio Y, Yamasawa K et al. p53 alteration is not an independent prognostic indicator, but affects the efficacy of adjuvant chemotherapy in human pancreatic cancer. J Surg Oncol 2003;82:111-20.
29. Hamanaka Y, Suehiro Y, Fukui M et al. Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer. Int J Cancer 2003;103:97-100.
30. Tomaino B, Cappello P, Capello M et al. Circulating autoantibodies to phosphorylated α-enolase are a hallmark of pancreatic cancer. J Proteome Res 2011;10:105-12.
31. Ohshio G, Suwa H, Imamura M. Clinical implication of anti-p53 antibodies and p53-protein in pancreatic disease. Int J Gastrointest Cancer 2002;31:129-35.